Saxenda represented the first time the FDA explicitly approved a GLP-1 compound for obesity treatment in non-diabetic patients, signaling regulatory recognition of weight loss benefits
A 2024 study published in the American Journal of Health-System Pharmacy found no significant differences in weight loss outcomes between patients using compounded versus brand name semaglutide over 24 weeks of treatment (Thompson et al., 2024)
These pathways act collectively to ensure behavior is matched to energy supplies and cellular stress is minimized
Unlike many medications, it does not rely on increasing blood flow, making it an effective option for individuals with low libido due to hormonal changes, stress, or other factors
Plant-Based Insulin Modulation Ceylon Cinnamon and Berberine help maintain a balanced response to glucose intake, supporting steady energy levels throughout the day.
A low fermentable oligo-di-mono saccharides and polyols (FODMAP) diet reduced pain and improved daily life in fibromyalgia patients
